Human Dopamine Receptor D3 (DRD3) CLIA Kit

Product specifications

CLIA Kits

Dopamine Receptor D3 (DRD3)

Human

Chemiluminescent

Quantitative

Sandwich

0.312 ng/ml - 20 ng/ml

< 0.113 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

5 × 96 tests

10 × 96 tests

Lyophilized

CLIA

Tissue homogenates, cell lysates and other biological fluids.

Shipped within 5-20 working days.

 Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

DRD3,D3DR,ETM1,FET1,D3 receptor,dopamine D3 receptor,dopaminergic receptor D3

CLIA Kits DRD3

RUO

The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

DRD3 is a G protein-coupled receptor (GPCR) of the D2-like family that couples to Gi/o proteins, inhibiting adenylate cyclase activity and reducing intracellular cyclic AMP (cAMP) levels. It is primarily expressed in limbic regions of the brain, including the ventral striatum, nucleus accumbens, and olfactory tubercle, where it regulates emotional behavior, reward processing, and cognitive function. DRD3 is involved in motivation, reinforcement learning, and drug addiction, where its dysregulation contributes to compulsive behaviors and substance abuse disorders. In schizophrenia, altered DRD3 signaling is associated with cognitive and behavioral deficits, and it is a target for atypical antipsychotics. DRD3 also plays a role in Parkinson’s disease, where it regulates motor control and is upregulated in response to dopaminergic neuron loss, contributing to dyskinesia. Outside the brain, DRD3 is expressed in peripheral tissues, including the kidney and immune cells, where it influences renal function and immune responses. DRD3 is a promising therapeutic target for neuropsychiatric disorders, Parkinson’s disease, and addiction, with specific agonists and antagonists under development to modulate its function.

Related Products

Rat DRD3 (Dopamine Receptor D3) ELISA Kit

Ver Producto

Dopamine Receptor D3 (DRD3) Antibody

DRD3 Antibody is a Rabbit Polyclonal antibody against DRD3. This gene encodes the D3 subtype of the five (D1-D5) dopamine receptors. The activity of the D3 subtype receptor is mediated by G proteins which inhibit adenylyl cyclase. This receptor is localized to the limbic areas of the brain, which are associated with cognitive, emotional, and endocrine functions. Genetic variation in this gene may be associated with susceptibility to hereditary essential tremor 1. Alternative splicing of this gene results in transcript variants encoding different isoforms, although some variants may be subject to nonsense-mediated decay (NMD).

Ver Producto

Human Dopamine Receptor D3 (DRD3) ELISA Kit

Human Dopamine Receptor D3 (DRD3) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Dopamine Receptor D3 (DRD3) concentrations in tissue homogenates and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Dopamine Receptor D3 (DRD3)

Ver Producto